Article

In vitro antileishmanial and antitrypanosomal activities of flavanones from Baccharis retusa DC. (Asteraceae).

Instituto de Ciências Ambientais, Químicas e Farmacêuticas, Universidade Federal de São Paulo, Diadema, SP, Brazil.
Experimental Parasitology (impact factor: 2.12). 11/2011; 130(2):141-5. DOI:10.1016/j.exppara.2011.11.002
Source: PubMed

ABSTRACT Leishmaniasis and Chagas' are parasitic protozoan diseases that affect the poorest population in the world, causing a high mortality and morbidity. As a result of highly toxic and long-term treatments, novel, safe and more efficacious drugs are essential. In this work, the CH(2)Cl(2) phase from MeOH extract from the leaves of Baccharis retusa DC. (Asteraceae) was fractioned to afford two flavonoids: naringenin (1) and sakuranetin (2). These compounds were in vitro tested against Leishmania spp. promastigotes and amastigotes and Trypanosoma cruzi trypomastigotes and amastigotes. Compound 2 presented activity against Leishmania (L.) amazonensis, Leishmania (V.) braziliensis, Leishmania (L.) major, and Leishmania (L.) chagasi with IC(50) values in the range between 43 and 52 μg/mL and against T. cruzi trypomastigotes (IC(50)=20.17 μg/mL). Despite of the chemical similarity, compound 1 did not show antiparasitic activity. Additionally, compound 2 was subjected to a methylation procedure to give sakuranetin-4'-methyl ether (3), which resulted in an inactive compound against both Leishmania spp. and T. cruzi. The obtained results indicated that the presence of one hydroxyl group at C-4' associated to one methoxyl group at C-7 is important to the antiparasitic activity. Further drug design studies aiming derivatives could be a promising tool for the development of new therapeutic agents for Leishmaniasis and Chagas' disease.

0 0
 · 
0 Bookmarks
 · 
74 Views

Keywords

Baccharis retusa DC
 
Chagas' disease
 
chemical similarity
 
compound 2
 
drug design studies
 
efficacious drugs
 
hydroxyl group
 
Leishmania spp
 
Leishmaniasis
 
methoxyl group
 
methylation procedure
 
naringenin
 
new therapeutic agents
 
obtained results
 
poorest population
 
promastigotes
 
promising tool
 
sakuranetin
 
sakuranetin-4'-methyl ether
 
Trypanosoma cruzi trypomastigotes